沙利度胺曾因其致畸作用而被禁用,但近年来的基础研究和临床试验让人们对它有了新的认识.在恶性肿瘤的治疗中,沙利度胺也扮演着越来越重要的角色,其免疫调节以及抗血管新生作用在治疗骨髓增生异常综合征上取得了一定的疗效.作者就近年来沙利度胺治疗骨髓增生异常综合征的研究进展作一综述.

[1] LAZARINI M,TRAINA F,WINNISCHOFER S M,et al.Effects of thalidomide on long-term bone marrow cultures from patients with myelodysplastic syndromes:Induction of IL-10 expression in the stromal layers[J].Leuk Res,2011,35(8):1102-1107.
[2] HERNANDEZ MDE O,FULCO TDE O,PINHEIRO RO,et al.Thalidomide modulates Mycobacterium leprae-induced NF-κB pathway and lower cytokine response[J].Eur J Pharmacol,2011,670(1):272-279.
[3] KEIFER J A,GUTTRIDGE D C,ASHBURNER B P,et al.Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity[J].J Biol Chem,2001,276(25):22382-22387.
[4] MAJUMDAR S.Thalidomide suppresses NF-κB activation induced by TNF and H2O2,but not that activated by ceramide,lipopolysaccharides,or phorbol ester[J].J Immunol,2002,168(3):2644-2684.
[5] DREDGE K,MARRIOTT J B,MACDONALD C D,et al.Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects[J].Br J Cancer,2002,87(10):1166-1172.
[6] RAZA A,MEYER P,DUTT D,et al.Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes[J].Blood,2001,98(4):958-65.
[7] MORENO A A,GEYER S,LI C Y,et al.Multicenter phase Ⅱ trial of thalidomide in adult patients with myelodysplastic syndromes[J].Blood,2002,100(11):96A-96A.
[8] TAMBURINI J,ELIE C,PARK S,et al.Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes[J].Leuk Res,2009,33(4):547-550.
[9] WEI W,ZHOU F,ZHANG Y,et al.A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes[J].LeuK Res,2012,36(6):715-719.
[10] RAZA A,MEHDI M,ALI F,et al.Combination of 5-Azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia[J].Cancer,2008,113(7):1596-604.
[11] XIAO Z,XU Z,ZHANG Y,et al.Cyclosporin A and thalidomide in patients with myelodysplastic syndromes:results of a pilot study[J].Leuk Res,2011,35(1):61-65.
[12] MILLER A B,HOOGSTRATEN B,STAQUET M,et al.Reporting results of cancer trement[J].Cancer,1981,47(1):207-207.
[13] ADES L,FENAUX P.Immunomodulating drugs in myelodysplastic syndromes[J].Hematology Am Soc Hematol Educ Program,2011,2011(1):556-560.
[14] PELLEGRINO M.Thalidomide therapy for myelodysplastic syndromes:current status and future perspectives[J].Leuk Res,2004,28(4):325-332.